Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has captured the attention of analysts at Rodman & Renshaw, who have initiated coverage with a 'Buy' rating and an $8.00 price target. The rating is based on the company's lead drug candidate, Lucid-MS, which is being developed as a potential first-in-class non-immunomodulatory small molecule for the treatment of progressive multiple sclerosis (MS). This area of MS has limited therapeutic options, making Lucid-MS a significant prospect for addressing neurodegeneration and disability progression.
The $8.00 price target reflects the firm's valuation of Quantum BioPharma's development pipeline, with Lucid-MS at the forefront. The drug candidate has shown promise in preclinical models, demonstrating the ability to prevent and reverse myelin degradation, which is the underlying mechanism of MS. This mechanism of action is distinct from immunomodulatory approaches, offering a novel strategy that could potentially slow or halt disease progression.
According to the research note, the initiation of coverage underscores the potential of Lucid-MS to fill an unmet medical need. Progressive MS, including primary progressive and secondary progressive forms, affects a significant number of patients who often have limited treatment options. The current standard of care focuses on managing symptoms and reducing relapses, but there is a lack of therapies that directly target neurodegeneration and disability progression.
Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS through research and development. The company's pipeline also includes other drug candidates in various stages of development.
Beyond Lucid-MS, Quantum BioPharma has spun out its OTC version of UNBUZZD, a product aimed at alcohol misuse, to Unbuzzd Wellness Inc. (UWI). Quantum retains a 19.48% ownership stake in UWI as of June 30, 2026, and is entitled to royalty payments of 7% of sales from UNBUZZD until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The 'Buy' rating and price target from Rodman & Renshaw may boost investor confidence in Quantum BioPharma's prospects. The company's focus on addressing the underlying mechanisms of MS, rather than just managing symptoms, positions it as a potential leader in the field of neurodegenerative disease treatment. As clinical development progresses, the success of Lucid-MS could have a substantial impact on the lives of patients with progressive MS and on the company's valuation.
For more information on Lucid-MS, visit https://nnw.fm/8uqwL.
